Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (75 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > up date ! Private Placement
View:
Post by knoxt on Feb 14, 2024 8:01am

up date ! Private Placement

________________________________________

BULLETIN V2024-0495

THERALASE TECHNOLOGIES INC. ("TLT")
BULLETIN TYPE:  Private Placement-Non-Brokered
BULLETIN DATE:  February 13, 2024
TSX Venture Tier 2 Company

TSX Venture Exchange has accepted for filing documentation with respect to a Non-Brokered Private Placement announced on February 5, 2024:

Number of Shares:

6,666,670 shares
 

Purchase Price:

$0.18 per share
 

Warrants:

6,666,670 share purchase warrants to purchase 6,666,670 shares
 

Warrant Exercise Price:

$0.25 for a five-year period
 

Number of Placees:

35 placees

Insider / Pro Group Participation:

     

Placees

# of Placee (s)

Aggregate # of Shares

     

Aggregate Existing Insider
Involvement:

7

1,310,502

Aggregate Pro Group Involvement:

N/A

N/A

 

Aggregate
Cash Amount

Aggregate #

of Shares

Aggregate #

of Warrants

Finder's Fee:

$1,500

N/A

4,166 Warrants

Finder's Warrants Terms: Each warrant entitles the holder to purchase one common share at the price of $0.25 for period of 5 years from the date of issuance.

The Company issued a news release on February 5, 2024 confirming closing of the private placement.

Comment by managementfirst on Feb 14, 2024 8:27am
NICE!
Comment by DJDawg on Feb 14, 2024 8:31am
I like that they found 28 non-insiders keen to join!
Comment by Sunvalley on Feb 14, 2024 9:23am
I believe that it bodes well for the future now that a lot of "sugar daddys" are aligning themselves with Management and buying into the cash raises. Seems that a lot of people besides us are now realizing the groundbreaking nature of TLT,s science achievements and the tremendous possibilities at hand. We have not yet lit up the room but we are now fumbling with the switches. 
Comment by Longholder99 on Feb 14, 2024 10:01am
Probably doctors.
Comment by Legit62 on Feb 14, 2024 10:26am
Great sign IMO, tells me we are very close
Comment by Oilminerdeluxe on Feb 14, 2024 10:28am
Feel free to drop more updates soon, Roger.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 75 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 72 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250